WO1995024907A3 - Pharmaceutical compositions containing laminarin sulfate - Google Patents

Pharmaceutical compositions containing laminarin sulfate Download PDF

Info

Publication number
WO1995024907A3
WO1995024907A3 PCT/GB1995/000515 GB9500515W WO9524907A3 WO 1995024907 A3 WO1995024907 A3 WO 1995024907A3 GB 9500515 W GB9500515 W GB 9500515W WO 9524907 A3 WO9524907 A3 WO 9524907A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfate
laminarin sulfate
inhibition
sodium
pharmaceutical composition
Prior art date
Application number
PCT/GB1995/000515
Other languages
French (fr)
Other versions
WO1995024907A2 (en
Inventor
Israel Vlodavsky
Hua-Quan Miao
Original Assignee
Hadasit Med Res Service
Whalley Kevin
Israel Vlodavsky
Miao Hua Quan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service, Whalley Kevin, Israel Vlodavsky, Miao Hua Quan filed Critical Hadasit Med Res Service
Priority to AU18567/95A priority Critical patent/AU1856795A/en
Publication of WO1995024907A2 publication Critical patent/WO1995024907A2/en
Publication of WO1995024907A3 publication Critical patent/WO1995024907A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a pharmaceutical composition comprising sodium laminarin sulfate for mimicking heparin activity and for therapeutic use instead of heparin, in preventing restenosis by the inhibition of vascular smooth muscle cell proliferation; in accelerating wound healing by activating the release of active growth factors stored in the extra-cellular matrix; and for inhibiting tumor cell metastasis by inhibition of heparanase activity. The pharmaceutical composition includes a pharmaceutically effective amount of sodium laminarin sulfate, in combination with a pharmaceutically acceptable carrier, and wherein the molar ratio of sulfate groups to monosaccharide units in said laminarin sulfate is at least 1:1.
PCT/GB1995/000515 1994-03-13 1995-03-10 Pharmaceutical compositions containing laminarin sulfate WO1995024907A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU18567/95A AU1856795A (en) 1994-03-13 1995-03-10 Pharmaceutical compositions containing laminarin sulfate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL108951 1994-03-13
IL10895194A IL108951A0 (en) 1994-03-13 1994-03-13 Pharmaceutical compositions containing polysulfated polysaccharides

Publications (2)

Publication Number Publication Date
WO1995024907A2 WO1995024907A2 (en) 1995-09-21
WO1995024907A3 true WO1995024907A3 (en) 1995-11-09

Family

ID=11065921

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/000515 WO1995024907A2 (en) 1994-03-13 1995-03-10 Pharmaceutical compositions containing laminarin sulfate

Country Status (3)

Country Link
AU (1) AU1856795A (en)
IL (1) IL108951A0 (en)
WO (1) WO1995024907A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO104496A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Angiogenic inhibitory compounds
WO1998014169A1 (en) 1996-09-30 1998-04-09 Brigham & Women's Hospital Methods and compounds for treatment of abnormal uterine bleeding
FR2816213B1 (en) 2000-11-03 2005-04-22 Goemar Lab Sa ANTI-INFLAMMATORY DRUG AND SCARING
GB0112649D0 (en) * 2001-05-24 2001-07-18 Isis Innovation Macrophage receptor
US6660722B2 (en) * 2001-11-30 2003-12-09 Laboratoires Goemar S.A. Therapeutical treatments
FR2900577B1 (en) * 2006-05-04 2008-09-12 Goemar Lab Sa NEW MEDICAMENTS FOR TREATMENTS AGAINST HERPES VIRUS

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
B. JOLLES ET AL.: "ffects of sulphated degraded laminarin on experimental tumour growth", BR. J. CANCER, vol. 17, pages 109 - 115 *
D.H.PAPER ET AL.: "Effects of laminarin sulphates on transforming growth factor and basic fibroplast growth factor", PLANTA. MED., vol. 58, no. sup1, pages A585 - A586 *
DAVID HASDAI ET AL.: "The non-antithrombotic therapeutic potential of heparin and related haparinoids in cardiovascular diseases", CORONARY ARTERY DISEASE, vol. 5, no. 1, pages 81 - 91 *
MASAKI KOBAYASHI ET AL.: "Inhibition of blood-borne pulmonary metastasis by sulfated polysaccharides", TOKUSHIMA J. EXP. MED., vol. 26, no. 1-2, pages 41 - 51 *
R.PAUL ET AL.: "Inhibition of vascular smooth muscle cell proliferation in culture by pentosan polysulphate and related compounds", THROMB. RES., vol. 46, no. 6, pages 793 - 801 *
S.ALBAN ET AL.: "Synthesis of laminarin sulfates with anticagulant activity", ARZNEIMITTELFORSCHUNG, vol. 42, no. 8, pages 1005 - 1008 *

Also Published As

Publication number Publication date
WO1995024907A2 (en) 1995-09-21
AU1856795A (en) 1995-10-03
IL108951A0 (en) 1994-06-24

Similar Documents

Publication Publication Date Title
EP1447098A3 (en) Therapeutic inhibitor of vascular smooth muscle cells
CA2145093A1 (en) Therapeutic inhibitor of vascular smooth muscle cells
UA72882C2 (en) Pharmaceutical composition with controlled release of tolterodine
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
MY132705A (en) Novel compounds with analgesic effect
NZ321738A (en) 3-pyridine-2-heterocyclic substituted imidazoles and medicaments having anti-cancer and cytokine inhibitory activity
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
EP2295063A3 (en) Compositions and the use thereof the treatment of mitochondrial diseases
ES8402155A1 (en) Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
AU5090796A (en) Use of dextromethorphan or dextrorphan for the treatment of urinary incontinence
GEP20043334B (en) Hydrogel-Driven Drug Dosage Form
MX9307509A (en) Method and pharmaceutical preparation to reduce cell activity.
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
CA2125662A1 (en) Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
GEP20043162B (en) Derivatives of Isosorbid Mononitrate, Utilization as Vasodilator Agents with Reduced Tolerance
EP0137543A3 (en) Pharmaceutical composition for the therapy of peripheral arteriopathies
EP0754457A4 (en) Antiobestic agent
WO1995024907A3 (en) Pharmaceutical compositions containing laminarin sulfate
MY124465A (en) Reduction of infarct volume using citicoline
MX9805141A (en) USE OF INHIBITORS OF THE CELLULAR Na+/H+ EXCHANGER (NHE) FOR THE PREPARATION OF A DRUG FOR RESPIRATORY STIMULATION.
EP0787000A4 (en) Quinazolinone pharmaceuticals and use thereof
SI1567171T1 (en) Use of dextran sulfate for treating ibmir
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
WO2000076452A3 (en) Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase